Global capabilities

Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.

This week's research roundup feature: Microaggressions between members of a team occur often in medicine, even despite good intentions. Such situations call for difficult conversations that restore inclusivity, diversity, and a healthy work culture. These conversations are often hard because of the unique background, experiences, and biases of each person. In medicine, skillful navigation of these interactions is paramount as it influences patient care and the workplace culture.

After immigrating to the United State and becoming a U.S. citizen at the age of 18, Holocaust survivor Kurt Glover-Ettrich chose to give back to his new homeland by serving a 30-year career in the U.S. military. Today, as a Mayo Clinic volunteer, Kurt is giving back in new ways for the 22 years of regular care, treatment, and laboratory testing he’s received in response to the prostate cancer diagnosis that first brought him to Mayo Clinic.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss strategies for responsible innovation and how new standards for artificial intelligence (AI) safety will impact laboratory medicine and diagnostics.

Mayo Clinic Laboratories is excited to participate in the 65th ASH Annual Meeting & Exposition, which will take place in San Diego on Dec. 9–12, 2023.

Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.

This week's research roundup feature: Cytomegalovirus (CMV) is a significant cause of morbidity and mortality among immunocompromised hosts, including transplant recipients. Antiviral prophylaxis or treatment is used to reduce the incidence of CMV disease in this patient population; however, there is concern about increasing antiviral resistance.

In this month's "Hot Topic," Patricia Greipp, D.O., discusses fluorescence in situ hybridization, or FISH testing, particularly related to pediatric patients with hematologic malignancies.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Timothy Wiltshire, Ph.D., assistant professor of laboratory medicine and pathology in the division of transfusion medicine to discuss what’s new with CAR-T cells.

This page includes updates posted to Mayo Clinic Labs during the month of October.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the recent news of a possible cure for sickle cell disease, as well as gene editing therapies and their impact on the laboratory.

This week's research roundup feature: It is widely held that heart failure (HF) does not cause exertional hypoxaemia, based upon studies in HF with reduced ejection fraction, but this may not apply to patients with HF and preserved ejection fraction (HFpEF). Here, we characterize the prevalence, pathophysiology, and clinical implications of exertional arterial hypoxaemia in HFpEF.